Fostamatinib

Posted on 16th September 2020 by Karen Jennison

Grey

Brand Name(s):Tavlesse

Indication:Chronic immune thrombocytopenia refractory to other treatments

Rationale:4

Considered:Aug-20

Review Date:Jan-21

Comments:
NICE TA- expected Jan 2021